MedTrace Logo

Generalizability of REDUCE-IT Results to People of South Asian Descent With Atherosclerotic Cardiovascular Disease in Canada (REDUCE-IT Canada SA)

NCT05271591 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-03-27

No results posted yet for this study

Summary

The REDUCE-IT Canada SA Study is a cross-sectional study aiming to determine the proportion of study participants who meet the Health Canada-approved indication for icosapent ethyl (IPE;Vascepa®).

Conditions

Sponsors & Collaborators

  • HLS Therapeutics, Inc

    collaborator UNKNOWN

  • Canadian Medical and Surgical Knowledge Translation Research Group

    lead OTHER

Principal Investigators

  • Subodh Verma, MD, PhD · Unity Health Toronto

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-05
Primary Completion
2022-04-09
Completion
2022-04-09

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05271591 on ClinicalTrials.gov